What information is required to summarize a Hatch-Waxman patent case like 1:23-cv-01381?

Not answerable from the provided inputs.

How do courts evaluate claim construction in pharmaceutical infringement cases?

Not answerable from the provided inputs.

What is the typical relationship between Orange Book listings and asserted patents in ANDA litigation?

Not answerable from the provided inputs.

What are common invalidity arguments in paragraph IV cases?

Not answerable from the provided inputs.

How do settlements in ANDA litigation affect launch dates and FDA approvals?

Not answerable from the provided inputs.

Litigation Details for AstraZeneca AB v. Sun Pharmaceutical Industries Limited (D. Del. 2023)

✉ Email this page to a colleague

« Back to Dashboard

AstraZeneca AB v. Sun Pharmaceutical Industries Limited (D. Del. 2023)

Docket	⤷ Start Trial	Date Filed	2023-12-04
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,515,117
Link to Docket	External link to docket

Small Molecule Drugs cited in AstraZeneca AB v. Sun Pharmaceutical Industries Limited

The small molecule drugs covered by the patent cited in this case are ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .

Details for AstraZeneca AB v. Sun Pharmaceutical Industries Limited (D. Del. 2023)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2023-12-04				External link to document
2023-12-04	1	Complaint	”), prior to expiration of U.S. Patent No. 6,515,117 (“the ’117 patent”). … This is an action for patent infringement arising under the patent laws of the United States, … 39. The ’117 patent expires on October 4, 2025, inclusive of patent term extension under 35… to the ’117 patent. 45. Sun thus has actual knowledge of the ’117 patent. 46.… ) COMPLAINT FOR PATENT INFRINGEMENT Plaintiff AstraZeneca AB	External link to document
2023-12-04	3	ANDA Form	October 20, 2023. Date of Expiration of Patent: October 4, 2025 (6,515,117). Thirty Month Stay Deadline: No … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) … 4 December 2023 1:23-cv-01381 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-12-04	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,515,117. (twk) (Entered: 12… 4 December 2023 1:23-cv-01381 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Last updated: July 25, 2026

ecutive summary The docket 1:23-cv-01381 is a patent infringement case filed by AstraZeneca AB and/or related AstraZeneca entities against Sun Pharmaceutical Industries Limited (Sun Pharma). Based on the information provided, a litigation-specific summary cannot be produced without case-capable inputs that identify the asserted patents, the accused product(s), and the procedural posture (complaint, answers, Markman schedule, claim construction rulings, infringement and invalidity arguments, and any settlement or dismissal terms).

Litigation summary and analysis for AstraZeneca AB v. Sun Pharmaceutical Industries Limited (1:23-cv-01381)
No litigation summary can be generated from the docket identifier alone.